Loading...
XHKG
1652
Market cap96mUSD
Jul 09, Last price  
1.02HKD
1D
2.00%
1Q
-20.93%
IPO
-56.96%
Name

Fusen Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XHKG:1652 chart
P/E
P/S
2.39
EPS
Div Yield, %
Shrs. gr., 5y
-1.32%
Rev. gr., 5y
-10.90%
Revenues
273m
-16.15%
368,634,000441,988,000452,580,000462,061,000407,388,000486,854,000385,664,000491,757,000565,608,000326,029,000273,365,000
Net income
-12m
L-93.76%
44,879,00095,073,00096,820,000101,882,00053,434,00070,131,00016,645,000-34,654,000-36,277,000-188,783,000-11,784,000
CFO
122m
-8.82%
69,804,000172,345,000133,206,00062,818,00020,390,000153,207,00047,766,000110,490,000-73,334,000133,730,000121,930,461
Dividend
Jun 07, 20220.0042 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Fusen Pharmaceutical Company Limited operates as an investment holding enterprise, primarily engaged in the manufacturing and distribution of a diverse range of pharmaceutical products across the People's Republic of China. Its extensive product portfolio includes specific cold remedies based on Shuanghuanglian, offered as both oral solutions and injections, alongside medications like flunarizine hydrochloride capsules and compound ferrous sulfate granules. The company further provides Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. Beyond these, Fusen actively researches, develops, produces, and markets a variety of proprietary Chinese medicines and modern Western pharmaceuticals, targeting conditions such as colds, fevers, cardiovascular ailments, and anemia. Additionally, the firm offers business management and advisory services. Fusen Pharmaceutical Company Limited was established in 2003 and is headquartered in Nanyang, China.
IPO date
Jul 11, 2018
Employees
1,121
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT